Abstract
547Background: Tamoxifen provides significant survival benefit in the adjuvant treatment of estrogen receptor-positive (ER+) breast cancer. However, its proliferative effect on the endometrium pote...
Highlights
The selective estrogen receptor modulator tamoxifen is one of the most frequently prescribed anticancer therapies worldwide
Written consent was obtained from participants before enrollment
A striking observation was the low event rate in the tamoxifen arm; the fraction of patients with abnormal endometrial pathology (6%), including its upper 95% confidence limit (13%), was much lower than the projected 30% in the trial design.[13,14,15]
Summary
The selective estrogen receptor modulator tamoxifen is one of the most frequently prescribed anticancer therapies worldwide. Two patients rate of endometrial hyperplasia in patients receiving estrogen replacement.[18] on the tamoxifen arm and 11 patients on the tamoxifen+MPA arm received incorrect or no treatment. To compare the addition of cyclical MPA at the same time as One patient died from a myocardial infarction judged to be tamoxifen compared with the control arm of tamoxifen alone, and treatment-related.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
